FlandersBio on Twitter

Follow us on Twitter

alliances - News

alliances - Nieuws

in het nederlands in english

FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.

ABLYNX AND TAISHO SIGN EXCLUSIVE LICENSE AGREEMENT FOR THE DEVELOPMENT AND COMMERCIALISATION OF ANTI-TNFa NANOBODY (OZORALIZUMAB) IN JAPAN

30.06.2015

Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that it has entered into an exclusive license agreement with Taisho Pharmaceutical Co., Ltd. ("Taisho") for the development and commercialisation of Ablynx's anti-TNFa Nanobody, ozoralizumab, in Japan, for the treatment of RA. read more

arGEN-X and LEO Pharma Enter into Alliance to Develop Antibody-based Treatments for Skin Conditions

21.05.2015

arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies to treat cancer and severe autoimmune diseases, and LEO Pharma A/S, a global healthcare company dedicated to helping people achieve healthy skin, today announced an alliance in which they will collaborate to develop innovative antibody-based solutions for the treatment of chronic inflammation underlying many skin conditions. read more

Knowledge for Growth – ITM Antwerp seeks allies against tropical diseases

20.05.2015

On Thursday 21 May 2015, the Institute of Tropical Medicine in Antwerp (ITM) takes part in the 11th edition of Europe’s leading regional life sciences convention Knowledge for Growth, organised by FlandersBio. Using the slogan “the tropics are closer than you think”, ITM is seeking allies in the fight against infectious diseases affecting the world’s poorest, but which have an increasing global impact. read more

PMV and LSP enter into strategic partnership in life sciences

12.05.2015

ParticipatieMaatschappij Vlaanderen (PMV) and Life Science Partners (LSP) today announce entering into a strategic partnership to further build and strengthen Flanders’ life sciences industry, benefitting from each other’s complementary networks, skills and expertise. read more

Thrombogenics splitst kankerafdeling af

17.04.2015

Thrombogenics splitst zijn kankeronderzoek af in een apart bedrijf, Oncurious. Dat richt het samen met onderzoekscentrum VIB op. Oncurious gaat zich in een eerste fase toeleggen op de ontwikkeling van een medicijn tegen een bepaald type hersentumor bij kinderen. Een zeldzame maar zeer agressieve kanker. read more

ThromboGenics and VIB launch New Oncology Company

14.04.2015

ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces the foundation of Oncurious NV, a new oncology company that will develop TB-403 for the treatment of pediatric brain tumors. VIB, a leading life sciences institute in Flanders (Belgium), will become a shareholder alongside ThromboGenics in this new oncology venture. ThromboGenics will be the majority shareholder. read more

Galapagos regains rights to GLPG1690, announces end of alliance with Janssen

17.03.2015

Galapagos NV (Euronext: GLPG) announced that Janssen Pharmaceutica NV and Galapagos have mutually agreed to terminate the inflammation alliance and option agreements between the companies. Galapagos views the molecules emerging from the alliance as strong additions to its growing proprietary pipeline. Among others, all rights to candidate drug GLPG1690, a selective autotaxin inhibitor, return to Galapagos. Galapagos has successfully completed a First-in-Human Phase 1 trial for GLPG1690 and is preparing a Phase 2 clinical trial in idiopathic pulmonary fibrosis (IPF). read more

arGEN-X Announces Advancement of Therapeutic Antibody Alliance with Shire

11.12.2014

arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that its partner Shire has exercised its option to advance into preclinical development one or more product candidates created out of a 2012 therapeutic antibody alliance between the two companies. As a result of the exercise, arGEN-X will receive a milestone payment from Shire. read more

CARDIO3 BIOSCIENCES AWARDED PREFERRED ACCESS RIGHTS TO ALL MAYO CLINIC CENTER FOR REGENERATIVE MEDICINE PORTFOLIO

08.10.2014

Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the discovery, development and commercialization of regenerative, protective and reconstructive therapies, announces today the signing of a preferred access agreement with Mayo Clinic. Under this agreement, Mayo grants Cardio3 BioSciences preferred access to technologies developed in the Mayo Clinic Center for Regenerative Medicine, as well as select other Mayo technologies. This agreement is an expansion of a long-standing collaboration, which led to the development of C-Cure®; Cardio3 BioSciences’ product candidate now in advanced clinical trial testing (Phase III); an innovative cell therapy based on the discovery of the cardiopoiesis platform by the team of Andre Terzic, M.D., Ph.D. at Mayo Clinic. read more

Galapagos receives milestone in osteoarthritis alliance with Servier

05.08.2014

Galapagos NV (Euronext: GLPG) announced today the achievement of a second partial milestone, thereby completing the nomination of a new pre-clinical candidate in the osteoarthritis alliance with Servier. On March 7, Galapagos announced the receipt of €2M as the first partial milestone. Today's payment remains undisclosed and contributes to Group revenues in the first half of 2014. read more

Join E-news

Interested in a regular update of the life sciences and biotech sector in Flanders? Subscribe to our newsletter.

Subscribe now

Back to top

Print